Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As monotherapy for adults and children age 12 years or older with metastatic MSI-high or mismatch repair-deficient colorectal cancer after progression following fluoropyrimidine, oxaliplatin, and irinotecan.
LAMPGEN ANALYSIS
Why it matters
The FDA converted the previously authorized single-agent use to traditional approval.
What research teams should watch
Track this post-chemotherapy population separately from the broader same-day nivolumab–ipilimumab approval.
PRIMARY RECORDS